Exhibit 16.1

 

June 27, 2023

 

 

Office of the Chief Accountant

Securities and Exchange Commission

100 F Street, NE

Washington, D.C. 20549

 

 

Dear Sir/Madam:

 

We have read the statements included under Item 4.01 in the Form 8-K dated June 27, 2023 of GlobeStar Therapeutics Corporation (the “Company”) to be filed with the Securities and Exchange Commission regarding the change of auditors. We agree with such statements insofar as they relate to our firm.

 

 

Very truly yours,

 

/s/ M&K CPAS, PLLC

Houston, TX

 

---